New treatment approach for pancreatic cancer using modified Gemcitabine
Development and Testing of a Novel Biospecific using modified Gemcitibine to target and treat Pancreatic Cancer
This study is testing a new version of a cancer drug to see if it works better for people with pancreatic cancer, especially for Black/African American patients, by helping the medicine get into the cancer cells more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida Agricultural and Mechanical Univ NIH-funded |
| Lab location | 1 site (Tallahassee, United States) |
| Project ID | NIH-10931534 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with low survival rates, particularly among Black/African American patients. The approach involves modifying Gemcitabine to enhance its effectiveness by improving its transport into cancer cells and reducing its breakdown. The researchers will test this modified drug in patient-derived organoid models to evaluate its efficacy compared to traditional treatments. By targeting specific receptors on cancer cells, this research aims to provide a more effective therapy for patients suffering from this challenging disease.
Who could benefit from this research
Good fit: Ideal candidates for this research include Black/African American individuals diagnosed with pancreatic ductal adenocarcinoma.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While this approach is innovative, similar strategies targeting specific cancer receptors have shown promise in other types of cancer treatments.
Where this research is happening
Tallahassee, United States
- Florida Agricultural and Mechanical Univ — Tallahassee, United States (Active)
Researchers
- Principal investigator: Agyare, Edward Kwasi — Florida Agricultural and Mechanical Univ
- Study coordinator: Agyare, Edward Kwasi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.